Proactive Research analyst Emma Ulker says 's () full year 2019 results reflect a period of transition, as the company consolidated only six months of Venn revenues, with the focus being on integration and ongoing streamlining of the business, following the post–period acquisition of hVIVO in January.
Ulker says the outlook includes expanding its range of pharma services and completing the development of a COVID-19 HVC model which is already attracting the attention of the global pharma industry.
Click here to read Emma Ulker's latest update Open Orphan: Focused on a buoyant outlook
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE